

**Objectives:** To compare alternative methods for unanchored indirect comparisons of two interventions for overall survival when individual patient data (IPD) is available for both studies (IPD-IPD analyses), and when IPD is only available for one study and aggregate data (AD) for the other study (IPD-AD analyses). **Methods:** A case study comparing nivolumab with standard of care (SoC) in 3L small cell lung cancer was performed using the CheckMate032 trial and the Flatiron Health database to compare unanchored comparisons without population adjustment, IPD-IPD adjustment analyses using inverse probability treatment weighting (IPTW), regression adjustment (RA), and doubly robust methods (DRM<sub>IPD-IPD</sub>), and IPD-AD analyses using matching-adjusted indirect comparison (MAIC), simulated treatment comparison (STC), and a novel DRM<sub>IPD-AD</sub>. Relative treatment effects were expressed with Cox hazard ratios (HRs) and differences in restricted mean survival time (DRMST). A simulation study was performed evaluating the performance of the alternative methods in different scenarios. **Results:** Conditional HRs from RA differed from the marginal HRs from IPTW due to non-collapsibility. Therefore, estimates of DRMST in months were used as the relative treatment effect measure for the case study, which provides a collapsible estimand for DR estimates and comparison between methods DRMST with nivolumab versus SoC was higher for RA (3.22) than IPTW (2.72) and DRM<sub>IPD-IPD</sub> (2.71). MAIC, STC, and DRM<sub>IPD-AD</sub> estimates were similar (2.88; 2.92; 2.88) but with more uncertainty. The simulations found that when covariates differed substantially between studies, IPTW performed poorly in comparison to RA and DRM. **Conclusions:** Analysts should be aware of differences between marginal and conditional treatment effects when performing indirect comparisons of time-to-event outcomes; DRMST may be considered. Regression-based or DRM models may be preferable over other adjustment methods in cases with limited overlap in covariates between studies indirectly compared. Having IPD for both studies is preferable over having IPD for only one.

#### P44

##### NOVEL AND EXISTING FLEXIBLE SURVIVAL METHODS FOR NETWORK META-ANALYSES

Heeg B,<sup>1</sup> Garcia A,<sup>2</sup> van Beekhuizen S,<sup>3</sup> Verhoek A,<sup>1</sup> Roychoudhury S,<sup>4</sup> Cappelleri J,<sup>5</sup> Postma M,<sup>6</sup> Ouwens M<sup>7</sup>

<sup>1</sup>Ingress-health, Rotterdam, ZH, Netherlands, <sup>2</sup>Ingress-Health, rotterdam, Netherlands, <sup>3</sup>Ingress-Health, Rotterdam, Netherlands, <sup>4</sup>Pfizer, Inc., Gladstone, NY, USA, <sup>5</sup>Pfizer Inc, Newington, CT, USA, <sup>6</sup>University of Groningen, Groningen, Netherlands, <sup>7</sup>AstraZeneca, Gothenburg, Sweden

**Objectives:** The NICE Decision Support Unit has recently published technical support document 21, focusing on flexible survival methods and considering excess mortality. In this study, we research these flexible survival methods by assessing the effect of treatment on the different parameters of the distributions and the implementation of these flexible excess survival models in network meta-analyses (NMA). **Methods:** Standard parametric, mixture- (MCM) and non-mixture-cure (nMCM), piecewise, and splines are used for comparison. For the base case model, selection treatment coefficients were assigned to all parameters. The lowest leave-one-out information criterion (LOOIC) defined the base case parametric distribution per flexible model. The best-fitting distribution per model was rerun with treatment coefficients only for those larger than their standard deviation, and the one with the lowest LOOIC was considered the base case. Models were compared based on incremental mean survival and uncertainty. We used a network of four trials in previously treated advanced non-small cell lung cancer, comparing nivolumab vs. docetaxel, pembrolizumab vs. docetaxel, and two trials comparing atezolizumab vs. docetaxel. **Results:** The base case parametric distributions were log-logistic for standard parametric distribution, log-logistic for MCM, lognormal for nMCM, Weibull for mixture, log-logistic for piecewise, and log-logistic for spline models, with corresponding LOOICs 13418, 13417, 13420, 13417, 13418, and 13419. Regarding treatment effect parametrization, we applied no treatment effect on cure, for instance, but treatment effects on the scale for MCM and nMCMs. For piecewise, treatment effects were only applied on the second piece. After reducing the number of treatment effects, the mixture Weibull had the lowest LOOIC with 13407. The mean incremental survival with docetaxel as reference for mixture Weibull was 3.58 [95%CI 1.25,2.6], 0.45[0.19,0.93] and 2.67[0.2,9.48] for nivolumab, pembrolizumab and atezolizumab, respectively. For standard log-logistic these were 1.67 [0.94,2.55], 1.01[0.55,1.61], and 0.43[0.17,0.77]. **Conclusions:** Treatment effect specification is important as outcomes and uncertainty differ over the tested models.

##### Methodological Developments in Survival Analytic Methods: to Inform Cost-Effectiveness Models

#### P45

##### THE USE OF HISTORICAL CLINICAL TRIAL DATA TO INFORM SURVIVAL EXTRAPOLATION

Pham HA,<sup>1</sup> Smalbrugge D,<sup>2</sup> Kroij F,<sup>2</sup> Heeg B,<sup>1</sup> Ouwens M<sup>3</sup>

<sup>1</sup>Ingress-health, Rotterdam, ZH, Netherlands, <sup>2</sup>Ingress-health, Rotterdam, Netherlands, <sup>3</sup>AstraZeneca, Mölndal, O, Sweden

**Objectives:** Standard parametric distributions are commonly used for the extrapolation of survival data in cost-effectiveness analyses. However, survival data is often immature and uncertainty remains around the survival extrapolations. Mature historical data can be used to better predict survival beyond trial data. This study assessed two methods to incorporate historical data in the extrapolation of immature survival data. **Methods:** Immature data of a breast cancer trial comparing

pertuzumab+trastuzumab+docetaxel versus trastuzumab+docetaxel (follow-up time 38 months; data-cut 2015) was extrapolated and mature survival data (follow-up time 120 months; data-cut 2020) from the same trial was used to validate the extrapolations. The historical data was from a previous breast cancer trial including mature survival data of trastuzumab+docetaxel (follow-up time 50 months; data-cut 2005). Two methods to quantitatively inform the extrapolation of immature survival data with historical data were compared to standard parametric distributions: 1) historical shape parameter as informative prior for the shape of the immature data; 2) historical data as a third arm. Predictions were assessed with delta area under the curve (AUC) values based on the mature survival data. **Results:** Without priors, the delta AUC was 7.59, 1.62, 13.15, 8.32, 25.15, and with the historical arm the delta AUCs were 9.65, 4.38, 6.79, 8.26, 21.81, for Weibull, loglogistic, lognormal, exponential, and Gompertz, respectively. With priors, the delta AUC were 8.43, 3.37, 9.11, 23.68, for Weibull, loglogistic, lognormal, and Gompertz, respectively (as for exponential there is no shape parameter). The loglogistic distribution without priors predicted the immature data the best. For three out of five distributions, the extrapolations with a historical arm resulted in better predictions compared to the extrapolations without prior. **Conclusions:** The impact of external data on clinically plausible survival extrapolations can further be improved by using historical data with longer follow-up with treatment patterns similar to the current standard of care.

#### P46

##### EFFECTIVE USE OF RECONSTRUCTED SURVIVAL AND COMPARATIVE EFFECTIVENESS DATA: A CASE STUDY FROM ESTIMATING UNREPORTED SUBGROUP SURVIVAL IN ADVANCED STAGE GASTROINTESTINAL CANCERS

Alagoz O,<sup>1</sup> Xiao H,<sup>2</sup> Singh P,<sup>3</sup> Gricar J,<sup>3</sup> Dixon M,<sup>3</sup> Kim I,<sup>3</sup> Kurt M<sup>2</sup>

<sup>1</sup>University of Wisconsin-Madison, Madison, WI, USA, <sup>2</sup>Bristol Myers Squibb, Princeton, NJ, USA, <sup>3</sup>Bristol Myers Squibb, Lawrenceville, NJ, USA

**Objectives:** This study devises a systematic approach that can utilize aggregate level survival and comparative effectiveness data published from randomized controlled trials (RCT) to assist subgroup-specific health economic and meta-analyses. **Methods:** We developed a soft-constrained optimization model, which approximates the restricted mean survival time (RMST) for the overall population in each arm via weighted sum of the RMSTs of two subgroups of interest. Survivals of both subgroups in each arm were assumed to follow Weibull or log-logistic distribution. The constraint ensured that cumulative hazards between the arms were proportional for each subgroup at a sufficiently long pre-specified time point. Estimated subgroup-specific survival functions for the control arm were direct outputs of the model and were shifted by applying the reported hazard ratios from the forest plots to generate their counterparts for the intervention arm assuming proportional hazards between the arms. For validation, we tested our approach in a case study consisting of 10 distinct RCTs with reported subgroup-specific Kaplan-Meier (KM) curves from advanced stage gastrointestinal tumors. **Results:** Across all 48 subgroups, on average, loglogistic model performed equally or better than Weibull model in performance criteria comparing overall survival (OS) rates, median OS and RMSTs. Predicted survival curves laid within the 95% confidence intervals (CIs) of reported KM-curves in 75% and 81% of the time for Weibull and loglogistic models, respectively. Predicted median survivals were within the 95% CIs of the reported medians in 34 and 40 subgroups for Weibull and loglogistic models, respectively. Average relative gap between the predicted and reported RMSTs was 10% in both models. Predicted RMSTs were within the 95% CI of reported RMSTs in 34 and 37 subgroups for Weibull and loglogistic models, respectively. **Conclusions:** Our elicitation approach is effective and demonstrably reliable in deriving unreported subgroup survival with flexible time-varying hazard functions.

#### P47

##### A BAYESIAN HIERARCHICAL MIXTURE CURE MODELLING (MCM) FRAMEWORK FOR THE JOINT UTILIZATION OF PROGRESSION FREE SURVIVAL (PFS) AND OVERALL SURVIVAL (OS) IN ESTIMATING LONG-TERM SURVIVORSHIP RATES IN PREVIOUSLY UNTREATED METASTATIC MELANOMA: A CASE STUDY FROM CHECKMATE-067 TRIAL

Green N,<sup>1</sup> Paly V,<sup>2</sup> Youn JH,<sup>3</sup> Kurt M,<sup>4</sup> Moshyk A,<sup>4</sup> Gianluca Baio G<sup>1</sup>

<sup>1</sup>University College London, London, LON, UK, <sup>2</sup>ICON plc, New York, NY, USA, <sup>3</sup>ICON plc, Marlow, Bucks, UK, <sup>4</sup>Bristol Myers Squibb, Princeton, NJ, USA

**Objectives:** Differences in emergent survival plateaus between PFS and OS may imply clinically unintuitive dichotomy between the resulting proportions of long-term survivors (LTS) when they are analyzed separately via mixture cure models (MCM). We present a novel Bayesian hierarchical (BH) MCM framework assuming a dependency between PFS and OS to estimate LTS rates in CheckMate 067 and demonstrate its practical utility over frequentist MCMs in long-term QALY estimations. **Methods:** Frequentist and BH MCMs were fitted to PFS and OS data from the trial with minimum 60-months of follow-up. In the frequentist MCMs, PFS and OS were modelled separately whereas in BH MCMs both endpoints were modelled jointly with a shared LTS rate. In both approaches, background mortality rates were taken from World Health Organisation's age, gender and country-specific life tables and time-to-event outcomes for the non-LTS were modeled using a range of standard parametric distributions. Estimated incremental QALYs gains for nivolumab containing therapies versus ipilimumab under both approaches were compared using